305 related articles for article (PubMed ID: 19375783)
1. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma.
Hernández V; Alvarez M; de la Peña E; Amaruch N; Martín MD; de la Morena JM; Gómez V; Llorente C
Urology; 2009 Jun; 73(6):1306-10. PubMed ID: 19375783
[TBL] [Abstract][Full Text] [Related]
2. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
3. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
4. Watchful waiting policy in recurrent Ta G1 bladder tumors.
Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
6. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
7. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
8. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
9. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
Holmang S; Johansson SL
J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
[TBL] [Abstract][Full Text] [Related]
10. [Mid-term results of a program for the monitoring of superficial bladder tumors].
Paez Borda A; Luján Galán M; Llanes González L; Gómez de Vicente JM; Berenguer Sánchez A
Arch Esp Urol; 1999 Apr; 52(3):229-34; discussion 234-5. PubMed ID: 10371738
[TBL] [Abstract][Full Text] [Related]
11. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
[TBL] [Abstract][Full Text] [Related]
12. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
13. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
[TBL] [Abstract][Full Text] [Related]
14. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
Ather MH; Zaidi M
Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction.
Ham WS; Kim WT; Jeon HJ; Lee DH; Choi YD
J Urol; 2009 Apr; 181(4):1594-9; discussion 1599. PubMed ID: 19230913
[TBL] [Abstract][Full Text] [Related]
16. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases.
Toll AD; Epstein JI
Am J Surg Pathol; 2012 Jul; 36(7):1081-6. PubMed ID: 22510761
[TBL] [Abstract][Full Text] [Related]
17. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion.
Lee CT; Dunn RL; Ingold C; Montie JE; Wood DP
Urology; 2007 Jun; 69(6):1068-72. PubMed ID: 17572188
[TBL] [Abstract][Full Text] [Related]
18. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.
Lee TK; Chaux A; Karram S; Miyamoto H; Miller JS; Fajardo DA; Epstein JI; Netto GJ
Hum Pathol; 2011 Nov; 42(11):1799-803. PubMed ID: 21777949
[TBL] [Abstract][Full Text] [Related]
19. Urothelial papilloma of the bladder. Clinical and biologic implications.
Cheng L; Darson M; Cheville JC; Neumann RM; Zincke H; Nehra A; Bostwick DG
Cancer; 1999 Nov; 86(10):2098-101. PubMed ID: 10570437
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.
Canales BK; Anderson JK; Premoli J; Slaton JW
J Urol; 2006 Jan; 175(1):74-7. PubMed ID: 16406874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
